阿帕替尼联合化疗治疗晚期胃癌的临床研究  

Clinical study of Apatinib combined chemotherapy in the treatment of advanced gastric cancer

作　　者：朱华云[1] 孙小峰[1] 周青[1] 陈凌翔[1] 陈嘉[1] 吴平平[1] 

机构地区：[1]江苏省肿瘤医院肿瘤内科,江苏南京210009

出　　处：《中国肿瘤外科杂志》2016年第6期394-396,共3页Chinese Journal of Surgical Oncology

基　　金：江苏省干部保健科研项目(BJ15029);江苏省中医药局科技项目(YB2015170)

摘　　要：目的研究阿帕替尼联合化疗治疗晚期胃癌的临床疗效和不良反应。方法 2014年7月至2016年7月,选择既往化疗失败、疾病进展或复发转移入住江苏省肿瘤医院的晚期胃癌患者,分别采用阿帕替尼加以紫杉类、伊立替康类和氟尿嘧啶类药物为基础的化疗方案,另选择同期未接收阿帕替尼的化疗患者作为对照组,评价阿帕替尼联合化疗的治疗效果,并对不良反应结果进行分析。结果共入组71例,均可以评价疗效。其中39例仅接受化疗（对照组）,32例为阿帕替尼加化疗（实验组）。对照组的客观缓解率为15.4%,疾病控制率56.4%;实验组的客观缓解率为50.0%,疾病控制率84.4%。治疗过程中可见蛋白尿、高血压、白细胞减少、贫血等不良反应,但多为0-Ⅱ度。结论阿帕替尼联合化疗能够提高晚期胃癌的治疗效果,且不良反应可控。Objective To investigate the clinical efficacy and side-effect of Apatinib combined with chemotherapeutic agents in the treatment of advanced gastric cancer.Methods Patients with advanced gastric cancer adopted a Apatinib and Taxel,Irinotecan or Fluorouracil-based combination chemotherapy regimen.Concurrent patients who did not receive Apatinib were chosen as control group.The therapeutic efficacy and side-effect of Apatinib were evaluated.Results 71 patients were able to evaluate the clinical efficacy.The objective response rate（ ORR） and the disease control rate（ DCR） for patients receiving chemotherapy only（ control group） were 15.4% and 56.4%.ORR and DCR for those receiving Apatinib combined chemotherapy were50.0% and 84.4%,respectively.Side-effects were proteinuria,hypertension,anemia and others.Most of them were ranked as class 0 - Ⅱ.Conclusions Apatinib combined chemotherapy can improve the treatment of advanced gastric cancer with tolerable side-effects.

关 键 词：晚期胃癌 阿帕替尼 联合化疗 

分 类 号：R735.2[医药卫生—肿瘤]